The Stryker® IRF Light Source and SafeLight Cable are indicated for use to provide real-time endoscopic visible and near-infrared fluorescence imaging. The Stryker® IRF Light Source and SafeLight Cable enable surgeons to perform minimally invasive surgery using standard endoscope visible light as well as visual assessment of vessels, blood flow and related tissue perfusion, and at least one of the major extra-hepatic bile ducts (cystic duct, common bile duct and common hepatic duct), using near infrared imaging.

Fluorescence imaging of biliary ducts with the Stryker® IRF Light Source and SafeLight Cable is intended for use with standard of care white light and, when indicated, intraoperative cholangiography. The devices are not intended for standalone use for biliary duct visualization.

Device Description

The Stryker® Infrared Fluorescence (IRF) Imaging System is an endoscopic illumination and imaging system for real-time high definition (HD) visible light and near-infrared dye fluorescence imaging of indocyanine green (ICG) used during minimally invasive surgery. The Stryker Infrared Fluorescence (IRF) Imaging System consists of the following main components:

-A light source console and a light cable for outputting light within a visible light spectrum as well as near-infrared light spectrum.
A camera control unit for processing near-infrared and visible light images. -
-A coupler that is attached to the laparoscope and a camera head. It is optimized for nearinfrared fluorescence imaging in addition to visible light imaging.
A laparoscope for visible light and near-infrared light illumination and imaging. -
A Fluorescence ICG Kit containing IC-Green® drugs and Aqueous Solvents -

The Stryker system uses an illuminator with a laser light source to illuminate the area of surgery. The ICG is administered intravenously prior to image obtainment. A laser light is illuminated to the site of the surgery using a laparoscope. Upon the absorption of laser light, the ICG passing through the vessels are excited causing an infrared light to be emitted. The camera system captures the infrared emission, processes the image and displays it on a surgical display.

AI/ML Overview

The provided text is a summary of the 510(k) premarket notification for the Stryker® IRF Light Source and Safelight Cable. While it details performance testing, it does not present a table of acceptance criteria or specific reported device performance metrics in a quantitative manner as typically expected for answering such a question. However, I can extract information related to the studies mentioned.

Here's an analysis based on the provided document:

Acceptance Criteria and Reported Device Performance

The document summarizes that the device's safety and performance were evaluated and verified in accordance with design specifications and applicable performance standards. However, it does not explicitly list specific quantitative acceptance criteria or corresponding reported device performance values in a table format. Instead, it refers to general compliance with standards and successful testing.

General Categories of Verification/Validation:

Biocompatibility
Sterilization Validation
Electrical Safety and Electromagnetic Compatibility (EMC)
Software Validation
Bench Performance Testing
Animal Testing (in-vivo fluorescence imaging capability)
Clinical Literature Evaluation
Investigator Initiated Clinical Study

Study Information

A table of acceptance criteria and the reported device performance
As mentioned above, the document does not provide a specific table with quantitative acceptance criteria and reported device performance. It broadly states that the device was "evaluated and verified in accordance with design specifications and applicable performance standards" and met these.
Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Investigator Initiated Clinical Study:
  - Sample Size: Not specified in the provided text.
  - Data Provenance: Conducted at The Ohio State University (USA). Stated as a "non-significant risk study."
  - Retrospective/Prospective: Not explicitly stated, but "investigator initiated clinical study" usually implies a prospective design.
- Animal Testing: Sample size not specified. Provenance not specified.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts
The document does not provide details on the number or qualifications of experts used to establish ground truth for any of the studies mentioned (clinical or animal).
Adjudication method (e.g. 2+1, 3+1, none) for the test set
The document does not specify any adjudication method for the test set, or for establishing ground truth in the clinical study.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
The document does not mention an MRMC comparative effectiveness study involving human readers and AI assistance. The device in question (Stryker® IRF Light Source and SafeLight Cable) is an imaging system, not an AI diagnostic tool.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
The device is an imaging system designed to be used by surgeons for visual assessment. It is not an "algorithm only" device. Therefore, a standalone algorithm performance test (as might be performed for an AI diagnostic algorithm) is not applicable or described. The clinical study and animal testing evaluated the system's ability to provide the intended fluorescence imaging data for human interpretation.
The type of ground truth used (expert consensus, pathology, outcomes data, etc.)
- For the "investigator initiated clinical study" and "animal testing," the type of ground truth is not explicitly defined in the provided text. However, given the indications for use (visual assessment of vessels, blood flow, tissue perfusion, and major extra-hepatic bile ducts using near-infrared imaging), the ground truth would likely be established by:
  - Direct visual confirmation during surgery (for vessels, blood flow, tissue perfusion, and bile ducts), possibly compared to standard white light imaging or intraoperative cholangiography.
  - In animal studies, potentially histopathology or other established physiological methods to confirm perfusion or anatomical structures.
- The document mentions fluorescence imaging of biliary ducts is "intended for use with standard of care white light and, when indicated, intraoperative cholangiography," suggesting these existing methods serve as a comparative ground truth.
The sample size for the training set
The document does not mention a training set sample size. This is because the Stryker® IRF Light Source and SafeLight Cable is a hardware imaging system, not a machine learning or AI-based diagnostic algorithm that typically requires a training set.
How the ground truth for the training set was established
Not applicable, as no training set for an algorithm is mentioned or implied for this device.

Summary

{0}------------------------------------------------

Image /page/0/Picture/1 description: The image shows the seal of the Department of Health & Human Services (HHS) of the United States. The seal features the department's name, "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA," arranged in a circular pattern around the edge. At the center of the seal is a stylized emblem consisting of three human profiles facing to the right, stacked on top of each other, representing the department's focus on health and human well-being.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002

December 2, 2014

Stryker Endoscopy Mr. Golnaz Moeini Senior Regulatory Affairs Analyst 5900 Optical Court San Jose, California 95138

Re: K142310

Trade/Device Name: Stryker® IRF Light Source and Safelight Cable Regulation Number: 21 CFR 876.1500 Regulation Name: Endoscope and accessories Regulatory Class: Class II Product Code: OWN Dated: November 4, 2014 Received: November 5, 2014

Dear Mr. Moeini:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical

{1}------------------------------------------------

device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

for

Sincerely yours,

David Krause -S

Binita S. Ashar, M.D., M.B.A., F.A.C.S. Director Division of Surgical Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{2}------------------------------------------------

Indications for Use

510(k) Number (if known) K142310

Device Name

Stryker® IRF Light Source and SafeLight Cable

Indications for Use (Describe)

Type of Use (Select one or both, as applicable)

X Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

CONTINUE ON A SEPARATE PAGE IF NEEDED.

This section applies only to requirements of the Paperwork Reduction Act of 1995.

DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov

"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."

{3}------------------------------------------------

Section 5. 510(k) Summary

1. General Information

510(k) Sponsor	Stryker Endoscopy
Address	5900 Optical CourtSan Jose, CA 95138
FDA Registration Number	2936485
Correspondence Person	Golnaz MoeiniSr. Regulatory Affairs AnalystStryker Endoscopy
Contact Information	Email: golnaz.moeini@stryker.comPhone: 408-754-2755
Date Prepared	November 04, 2014

2. Proposed Device

Proposed Device:

Proprietary Name	Stryker® Infrared Fluorescence (IRF) Imaging System [consists of: IRF Light Source and SafeLight Cable, 1488 Camera Control Unit, IRF Coupler, IRF Laparoscope, and Fluorescence ICG Kit]
Common Name	Light Source, Illuminator
Classification Name	Confocal Optical Imaging
Regulation Number	21 CFR 876.1500
Product Code	OWN
Regulatory Class	II

3. Predicate Device

Predicate Device

Proprietary Name	Intuitive Surgical® da Vinci® Imaging Vision System(K124031)Video Camera with Infrared Compatibility (K132785)Stryker® Laparoscope (K910132)
Premarket Notification	K124031 K132785 K910132
Classification Name	Confocal Optical Imaging
Regulation Number	21 CFR 876.1500
Product Code	OWN
Regulatory Class	II

{4}------------------------------------------------

Device Description 4.

-A light source console and a light cable for outputting light within a visible light spectrum as well as near-infrared light spectrum.
A camera control unit for processing near-infrared and visible light images. -
-A coupler that is attached to the laparoscope and a camera head. It is optimized for nearinfrared fluorescence imaging in addition to visible light imaging.
A laparoscope for visible light and near-infrared light illumination and imaging. -
A Fluorescence ICG Kit containing IC-Green® drugs and Aqueous Solvents -

Indications for Use ട്.

The Stryker® IRF Light Source and SafeLight Cable are indicated for use to provide real-time endoscopic visible and near-infrared fluorescence imaging. The Light Source and SafeLight Cable enable surgeons to perform minimally invasive surgery using standard endoscope visible light as well as visual assessment of vessels, blood flow and related tissue perfusion, and at least one of the major extra-hepatic bile ducts (cystic duct, common bile duct and common hepatic duct), using near infrared imaging.

Fluorescence imaging of biliary ducts with the Stryker® IRF Light Source and SafeLight Cable are intended for use with standard of care white light and, when indicated, intraoperative cholangiography. The devices are not intended for standalone use for biliary duct visualization.

Comparison of Technological Characteristics with the Predicate Device 6.

As noted above, the Stryker® Infrared Fluorescence (IRF) Imaging System is equivalent to the following cleared devices in terms of its indications for use, design technology and performance specification:

{5}------------------------------------------------

With respect to the light source console and light cable, the proposed Stryker illuminator console is substantially equivalent to Intuitive Surgical® da Vinci® Imaging Vision System (K124031) in laser light output and indication for use.

With respect to the use of a contrast drug agent (indocyanine green (ICG)), the proposed Stryker Infrared Fluorescence (IRF) Imaging System device is similar to the predicate Intuitive Surgical® da Vinci® Imaging Vision System (K124031) device in that the proposed device is also intended to be used with an FDA approved contrast agent drug, indocyanine green (ICC), to achieve the proposed indications for use.

With respect to the camera system, the proposed Stryker camera is substantially equivalent to Stryker® 1488 HD Video Camera with Infrared Compatibility (K132785) since they both consist of a camera control unit and a coupler component and are essentially the same in design and indication for use with minor modification to optimize near-infrared light image processing and transmission.

With respect to the laparoscopes, the proposed Stryker laparoscope is substantially equivalent to Stryker® Laparoscope (K910132) since they are both the same in design and indication for use with very minor modification to the proposed device to enhance near-infrared images.

The Stryker illuminator device is essentially using a similar laser illumination technology as the already cleared Intuitive Surgical® da Vinci® Imaging Vision System and has the same clinical use. The camera control unit, coupler and laparoscopes are optimized to enable the visualization of fluorescence imaging. The ICG drug has had a long history of use with an established safety track record. The information included in this submission will establish the substantial equivalency of the proposed devices to the specified predicates.

Performance Data 7.

Safety and performance of the Stryker® Infrared Fluorescence (IRF) Imaging System has been evaluated and verified in accordance with design specifications and applicable performance standards through biocompatibility assessment, electrical safety and EMC testing, software validation, bench testing and animal testing. Additionally, an investigator initiated clinical study was conducted with IRB oversight and approval as a non-significant risk study at The Ohio State University utilizing the proposed device (Stryker® Infrared Fluorescence (IRF) Imaging System). The result of this clinical study is published in Surgical Endoscopy Journal. Additional clinical evaluation supporting the safety and effectiveness of near-infrared fluorescence imaging system has been gathered and summarized in the clinical section 20, Performance Testing-Clinical, for the summary of the relevant clinical literatures). The following performance testing are conducted and summarized in this submission:

-Biocompatibility was assessed in accordance to ISO 10993-1:2009 Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process and related collateral standards for patient contacting materials.

{6}------------------------------------------------

The SafeLight Cable, IRF Coupler and IRF Laparoscopes are designed to be sterilized using any of the following sterilization methods: STERRAD® (100S /NX™/100NX™), Steris Amsco® V-PROM, and Ethylene Oxide (EO). The Sterilization validation for each sterilization method was assessed in accordance with ISO 14937:2009- Sterilization of health care products - General requirements for characterization of a sterilizing agent and the development, validation and routine control of a sterilization process for medical devices. For all sterile devices, the Sterility Assurance Level (SAL) is 10°.
Electrical Safety and electromagnetic compatibility testing was performed in accordance to IEC 60601-1:2005- Medical electrical equipment- Part 1: General requirements for basic safety and essential performance and IEC 60601-1-2:2007- Medical electrical equipment- Part 1-2: General requirements for basic safety and essential performance-Collateral Standard: Electromagnetic disturbances - Requirement and tests, respectively. Testing indicates that the proposed device conforms to the aforementioned voluntary standards.
The software validation activities were performed in accordance with IEC -62304:2006/AC: 2008- Medical device software – Software life cycle processes as well as the FDA Guidance documents, "Guidance for the Content of Premarket Submissions for Software Contained in Medical Devices".
Bench performance testing was conducted to ensure that the device functioned as intended and met design specifications and acceptance criteria. Test results obtained verified the safety and effectiveness of the devices per design specifications and applicable standards.
Animal testing conducted under Good Laboratory Practice (GLP) validated the in-vivo fluorescence imaging capability of the Stryker® Infrared Fluorescence (IRF) Imaging System.
A full clinical literature evaluation was performed to assess the safety and efficacy of -Stryker Infrared Fluorescence (IRF) Imaging System for near-infrared fluorescence cholangiography during laparoscopic cholecystectomy and for near-infrared fluorescence perfusion angiography.

Conclusion 8.

Based on the information submitted in this premarket notification, and based on the indications for use, technological characteristics, performance testing and technological comparison to the predicate devices, the Stryker® Infrared Fluorescence (IRF) Imaging System

{7}------------------------------------------------

raises no new questions of safety and effectiveness and is substantially equivalent to the predicate devices in terms of safety, efficacy and performance.

Regulation Number and Section

§ 876.1500 Endoscope and accessories.

(a)
Identification. An endoscope and accessories is a device used to provide access, illumination, and allow observation or manipulation of body cavities, hollow organs, and canals. The device consists of various rigid or flexible instruments that are inserted into body spaces and may include an optical system for conveying an image to the user's eye and their accessories may assist in gaining access or increase the versatility and augment the capabilities of the devices. Examples of devices that are within this generic type of device include cleaning accessories for endoscopes, photographic accessories for endoscopes, nonpowered anoscopes, binolcular attachments for endoscopes, pocket battery boxes, flexible or rigid choledochoscopes, colonoscopes, diagnostic cystoscopes, cystourethroscopes, enteroscopes, esophagogastroduodenoscopes, rigid esophagoscopes, fiberoptic illuminators for endoscopes, incandescent endoscope lamps, biliary pancreatoscopes, proctoscopes, resectoscopes, nephroscopes, sigmoidoscopes, ureteroscopes, urethroscopes, endomagnetic retrievers, cytology brushes for endoscopes, and lubricating jelly for transurethral surgical instruments. This section does not apply to endoscopes that have specialized uses in other medical specialty areas and that are covered by classification regulations in other parts of the device classification regulations.(b)
Classification —(1)Class II (special controls). The device, when it is an endoscope disinfectant basin, which consists solely of a container that holds disinfectant and endoscopes and accessories; an endoscopic magnetic retriever intended for single use; sterile scissors for cystoscope intended for single use; a disposable, non-powered endoscopic grasping/cutting instrument intended for single use; a diagnostic incandescent light source; a fiberoptic photographic light source; a routine fiberoptic light source; an endoscopic sponge carrier; a xenon arc endoscope light source; an endoscope transformer; an LED light source; or a gastroenterology-urology endoscopic guidewire, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 876.9.(2) Class I for the photographic accessories for endoscope, miscellaneous bulb adapter for endoscope, binocular attachment for endoscope, eyepiece attachment for prescription lens, teaching attachment, inflation bulb, measuring device for panendoscope, photographic equipment for physiologic function monitor, special lens instrument for endoscope, smoke removal tube, rechargeable battery box, pocket battery box, bite block for endoscope, and cleaning brush for endoscope. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807of this chapter, subject to the limitations in § 876.9.